©Reuters.
Neurocrine (NASDAQ:) Biosciences, Inc. (NASDAQ:NBIX) Chief Regulatory Officer Ingrid Delaet recently sold her shares in the company, according to a new SEC filing. On March 21, Delaet sold 5,000 shares at prices ranging from $145.00 to $145.24, for a total sale of approximately $725,320.
The transaction was conducted pursuant to a previously adopted Rule 10b5-1 trading plan on November 29, 2023. The plan would allow company insiders to set predetermined schedules for buying and selling stock to avoid accusations of insider trading. Company policy restricts Delaet from amending or changing the trading plan after its adoption.
On the same day, Delaet acquired 5,000 shares of Neurocrine Biosciences stock at a price of $103.52 per share, totaling $517,600. These shares are acquired through the exercise of options as part of the compensation package, with a portion of the options vesting monthly over a period of time.
Following these transactions, Delaet's direct ownership in the company changed, with the most recent SEC filings showing the balance of 7,507 shares owned after the sale and 27,049 shares remaining in derivative form, or per share. Reflects non-qualified stock options exercisable at $103.52. Shared and expires on February 13, 2033.
Neurocrine Biosciences Inc., based in San Diego, California, operates in the biotechnology field with a focus on developing treatments for neurological and endocrine-related diseases and disorders.
Investors and supporters of Neurocrine Biosciences may find this information valuable as it provides insight into the actions of key executives within the company and may influence investment decisions.
Investment Pro Insights
As Neurocrine Biosciences Inc. (NASDAQ:NBIX) continues to navigate the biotechnology space, the company's financial health and stock price performance remain important factors for investors. Neurocrine Biosciences has a market capitalization of approximately $13.96 billion and is a significant player in the industry. The company’s P/E ratio, which is a measure of current price to earnings per share, is 54.97, which is 40.93 when considering the trailing twelve months as of Q4 2023. This shows that the company's earnings are highly valued. at present.
InvestingPro data shows strong revenue growth of 26.76% over the past 12 months as of Q4 2023, reflecting the company's ability to grow its sales and market presence. There is. The company's gross profit margin for the same period was an impressive 67.96%, indicating that it efficiently controlled the costs associated with the products it sold.
Investors looking to understand the stock's recent performance would note that Neurocrine Biosciences Inc. is trading near its 52-week high price, with price hitting 94.53% of this high. This could indicate investor confidence in the company's prospects, or reflect broader market trends. For those interested in the company's future earnings potential, one tip from InvestingPro is that net income is expected to increase this year, which could be a positive indicator for future profitability. It emphasizes that there is gender.
Additionally, this stock generally trades with low price volatility, according to InvestingPro Tips, suggesting it may offer a more stable investment compared to other stocks in the Biotechnology sector . Additionally, it's worth noting that InvestingPro includes 14 additional tips for investors who want to dig deeper into the company's financial nuances. This could provide further insight into Neurocrine Biosciences' financial health and share price performance.
To access these insights and make more informed investment decisions, investors can use coupon codes. pro news 24 Get an extra 10% off your annual or biennial Pro and Pro+ subscriptions with InvestingPro.
This article was generated with the help of AI and reviewed by an editor. Please see our Terms of Use for more information.
